Los Angeles Capital Management LLC Has $1.28 Million Stock Position in Immunome, Inc. $IMNM

Los Angeles Capital Management LLC reduced its position in Immunome, Inc. (NASDAQ:IMNM) by 31.8% in the 4th quarter, Holdings Channel reports. The firm owned 59,417 shares of the company’s stock after selling 27,685 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Immunome were worth $1,276,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strs Ohio bought a new position in Immunome in the fourth quarter worth $64,000. Assetmark Inc. bought a new position in Immunome in the third quarter worth $39,000. BIT Capital GmbH bought a new position in Immunome in the third quarter worth $69,000. BNP Paribas Financial Markets lifted its position in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in Immunome in the third quarter worth $76,000. 44.58% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Immunome news, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the completion of the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime acquired 10,500 shares of the business’s stock in a transaction on Friday, June 5th. The shares were bought at an average cost of $19.45 per share, with a total value of $204,225.00. Following the completion of the acquisition, the director owned 43,415 shares of the company’s stock, valued at approximately $844,421.75. This trade represents a 31.90% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 139,438 shares of company stock valued at $2,964,664 in the last ninety days. Insiders own 7.21% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on IMNM shares. Barclays started coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price for the company. Stephens reduced their target price on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Immunome in a research report on Wednesday, May 13th. Finally, Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $18.16 on Thursday. The stock has a market cap of $2.06 billion, a PE ratio of -7.63 and a beta of 2.04. The business has a fifty day moving average of $21.92 and a two-hundred day moving average of $21.71. Immunome, Inc. has a 52-week low of $7.96 and a 52-week high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.